Decipher Biosciences

Executive Summary

Decipher Biosciences, operating under Veracyte, is a commercial-stage diagnostics company specializing in genomic tests for urologic cancers, primarily prostate and bladder cancer. Its flagship Decipher Prostate test analyzes tissue samples to provide prognostic and predictive insights, enabling personalized treatment decisions. The Decipher Bladder test similarly aids in risk stratification for bladder cancer patients. These tests leverage a proprietary genomic classifier to inform clinical management, helping avoid unnecessary treatments while improving outcomes. Decipher’s tests are supported by robust clinical validation and are incorporated into major clinical guidelines, positioning them as standard-of-care tools in urologic oncology. The company generates recurring revenue from test volumes and benefits from Veracyte’s commercial infrastructure and distribution network. With a strong value proposition for payers and providers, Decipher has achieved broad Medicare coverage, which drives adoption. The urologic diagnostics market is expanding, and Decipher is well-positioned to capture growth through test menu expansion and potential liquid biopsy applications. However, competition from other genomic tests and pricing pressure remain risks. Overall, Decipher represents a mature, profitable diagnostics platform with a clear path to sustained growth.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Decipher Bladder into NCCN Guidelines80% success
• Q4 2026Publication of Decipher Prostate long-term outcomes in high-risk patients70% success
• Q1 2027New partnership for companion diagnostic development with a pharma partner50% success